Welcome to our dedicated page for Entrada Therapeutics news (Ticker: TRDA), a resource for investors and traders seeking the latest updates and insights on Entrada Therapeutics stock.
Entrada Therapeutics reports clinical-stage biopharmaceutical developments tied to its intracellular genetic-medicine platform and Endosomal Escape Vehicle therapeutics. Company updates center on RNA-based and oligonucleotide programs for neuromuscular and inherited retinal diseases, including Duchenne muscular dystrophy programs for exon 44, 45, 50 and 51 skipping-amenable patients.
Recurring news includes clinical data and study progress for ELEVATE programs, updates on ENTR-601-44 and other DMD candidates, the partnered VX-670 program for myotonic dystrophy type 1, and pipeline expansion into ocular disease such as Usher syndrome. Financial results, cash runway commentary, investor conference participation and Nasdaq inducement equity grants also appear in company communications.
Entrada Therapeutics (Nasdaq: TRDA) announced its addition to the Russell 2000® and Russell 3000® Indexes, effective December 20, 2021. This inclusion follows the company's successful IPO in November 2021 and aims to enhance market awareness for its Endosomal Escape Vehicle (EEV™) therapeutics. The Russell indexes are benchmarks for investment strategies, with about $10.7 trillion in assets linked to them. This milestone is expected to broaden Entrada's visibility in the investment community, as it advances its EEV therapeutic candidates targeting previously inaccessible intracellular targets.
Entrada Therapeutics, Inc. (Nasdaq: TRDA) completed a successful upsized IPO, raising $208.7 million in November 2021, positioning the company for significant advancements. Financial results for Q3 2021 revealed cash and cash equivalents of $122.2 million, excluding IPO proceeds. R&D expenses rose to $10.5 million, driven by preclinical studies and higher personnel costs. G&A expenses also increased to $3.9 million, reflecting higher legal fees and personnel costs. The net loss for Q3 2021 was $14.4 million, compared to $7.0 million in Q3 2020, signaling increased operational investments.
Entrada Therapeutics (Nasdaq: TRDA) announced that CEO Dipal Doshi will participate in a fireside chat at the Evercore ISI 4th Annual HealthCONx Virtual Conference on December 2, 2021, at 12:10 p.m. ET. The event aims to showcase Entrada's focus on creating Endosomal Escape Vehicle (EEV™) therapeutics to tackle previously unaddressed intracellular targets. A live webcast of the chat will be available on the company's website, followed by a 90-day replay. Entrada is developing EEV therapeutics to enhance treatment for various diseases, including Duchenne muscular dystrophy.
Entrada Therapeutics, Inc. (Nasdaq: TRDA) announced the closing of its initial public offering, successfully selling 9,075,000 shares at $20.00 each, raising approximately $181.5 million. All shares were offered by Entrada. The offering commenced trading on October 29, 2021. Underwriters also hold an option for an additional 1,361,250 shares within 30 days. Goldman Sachs, Cowen, and Evercore acted as joint book-running managers for this offering. The company focuses on innovative Endosomal Escape Vehicle (EEV™) therapeutics targeting previously inaccessible intracellular diseases.
Entrada Therapeutics (Nasdaq: TRDA) has priced its upsized initial public offering (IPO) of 9,075,000 shares at $20.00 per share, aiming for gross proceeds of approximately $181.5 million. This marks a significant step for the biotechnology firm focused on Endosomal Escape Vehicle (EEV™) therapeutics. Trading is set to commence on October 29, 2021, with the offering expected to close on November 2, 2021. The underwriters hold an option for an additional 1,361,250 shares as part of the IPO.